CD274 and bullous pemphigoid: Cutaneous immune-related AEs occur in 20% to 40% of patients treated with PD-1/PD-L1 inhibitors.[1] The most common cutaneous complications are psoriasiform, eczematous, and lichenoid dermatoses.[2] Bullous pemphigoid (BP) constitutes an uncommon dermatological immune-related AE of PD-1/PD-L1 inhibitors.